While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy
Recent reports suggest that as of 2022, 12% of adults in the United States have taken a GLP-1 agonist for weight loss at some point
Anecdotal reports from healthcare providers and patient communities suggest that mild bruising may occur more frequently in everyday practice, though most cases are minor and resolve without intervention
According to the 2026 BMJ review, without this support, weight regain is nearly inevitableand all the health benefits gained during treatment will reverse within 1.4 to 1.7 years
Ginger root capsules (250-500mg) taken 2-3 times daily may help with overall digestive comfort
Tirzepatide delivers proven, FDA-approved results with years of safety data behind it